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We have examined dopaminergic cell survival after alteration of the subthalamic nucleus (STN) in methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys. The STN was lesioned with kainic acid
(B series) or underwent deep brain stimulation (DBS) at high frequency (C series). In another series, MPTP-
treated and non-MPTP-treated monkeys had no STN alteration (intact animals; A series). Animals were
treated with MPTP either after (B1, C1) or before (B2, C2) STN alteration. We also explored the long-term
( 7 months) effect of DBS in non-MPTP-treated monkeys (D series). Brains were aldehyde-fixed and processed
for routine Nissl staining and tyrosine hydroxylase immunocytochemistry.Our results showed that there were
significantly more (20^24%) dopaminergic cells in the substantia nigra pars compacta (SNc) of the MPTP-
treated monkeys that had STN alteration, either with kainic acid lesion or DBS, compared to the non-MPTP-
treated monkeys (intact animals). We suggest that this saving or neuroprotection was due to a reduction in
glutamate excitotoxicity, as a result of the loss or reduction of the STN input to the SNc. Our results also
showed that SNc cell number in the B1 and C1 series were very similar to those in the B2 and C2 series. In
the cases that had long-term DBS of the STN (D series), there was no adverse impact on SNc cell number.
In summary, these results indicated that STN alteration offered neuroprotection to dopaminergic cells that
would normally die as part of the disease process.
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Abbreviations: 6OHDA¼6h y d r o x y d o p a m i n e ;A C ^P C¼anterior commissure-posterior commissure; b¼Bs e r i e s ;
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SNr ¼substantia nigra pars reticulata; STN¼subthalamic nucleus; TH¼tyrosine hydroxylase; VTA ¼ventral tegmental area;
ZI¼zona incerta
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Introduction
Recent studies have suggested that glutamate excitotoxicity
contributes to dopaminergic cell death in the SNc in
Parkinson disease (PD; Lavoie and Parent, 1994; Blandini
et al., 2004). This suggestion is based on the increased
vulnerability of these cells to extracellular glutamate, due to
a mitochondrial complex I defect (Schapira, 2001). In
addition, there is evidence showing that after experimental
reductions of glutamatergic inputs or receptor activities in
the SNc of PD models, there is a saving of dopaminergic
cells. For example, when NMDA receptor antagonists are
infused into the SNc, the toxicity of MPTP on the
dopaminergic cells is blocked (Brouillett and Beal, 1993).
The same effect is achieved also by removing—whether
by lesion or DBS—the glutamatergic inputs to SNc,
namely those from STN (Hammond et al., 1983; Parent
and Smith, 1987) and pedunculopontine tegmental nucleus
(PpT; Saper and Loewy, 1982; Charara et al., 1996).
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 Both STN (Mitchell et al., 1989; Bergman et al., 1994;
Bezard et al., 1999) and PpT (Breit et al., 2001) inputs are
overactive in PD and hence presumed to impart glutamate
excitotoxicity in the SNc. Indeed, many studies have shown
that both lesion (Piallat et al., 1996; Nakao et al., 1999;
Chen et al., 2000; Carvalho and Nikhah, 2001; Paul et al.,
2004) or DBS (Maesawa et al., 2004) of the STN, prior to
parkinsonian insult, saves dopaminergic cells. Similarly,
in MPTP-treated monkeys with a prior PpT lesion, there
are many more dopaminergic cells evident compared to
controls (Takada et al., 2000). In addition, Temel and
colleagues (2006) have shown recently that in cases of
DBS of the STN in rats after parkinsonian insult
[6 hydroxydopamine (6OHDA)], there is a saving of
dopaminergic cells in the SNc also.
In this study, we explored the survival of dopaminergic
cells with STN alteration in MPTP-treated monkeys.
The STN was altered in two ways (i) the traditional
method of kainic acid ablation (B series) and (ii) DBS at
high frequency (C series). We used a subacute model of
MPTP treatment, one designed specifically for examining
dopaminergic cell survival (Ashkan et al., 2006). There were
two approaches. In one set of each series (B1, C1), there
was STN alteration before MPTP treatment. Removing
glutamatergic pathways prior to the parkinsonian insult is a
widely used experimental paradigm; it ensures that any
dopaminergic cell loss occurs entirely in the absence of the
excitotoxic pathway (e.g. Piallat et al., 1996; Maesawa et al.,
2004). In a second set of each series (B2, C2), there was
MPTP treatment followed by STN alteration. This is more
like the clinical reality, where cell loss due to insult occurs
prior to surgical intervention. In a final series (D series),
we examined the survival of dopaminergic cells under
chronic DBS of the STN in non-MPTP-treated animals.
Our results on this primate model of PD—the most
readily applicable to humans—will hopefully provide
insights into the neuroprotective effects of STN alteration
in PD cases.
Materials and methods
Subjects
Adult male macaque monkeys (Macaca fascicularis; Mauritius;
n¼28) weighing 3.4–8kg were used. Animals were maintained in
individual cages under controlled conditions of temperature
( 25 C) and light (12h light/dark cycle), were fed regularly on
a diet of fruit and biscuits and had free access to water.
The laboratory is authorized by the French Ministry of
Environment (Agreement N  B3851610003) and all experiments
were performed in accordance with the European Communities
Council Directive of 1986 (86/609/EEC) for care of laboratory
animals. All participants of the team had received proper training
and certification for animal experimentation. Every effort was
made to minimise animal suffering, while maximizing
data output.
Experimental design
There were four experimental series in this study:
A series (n¼3)
This series formed the intact group. One monkey had no MPTP
treatment (A1-1), while the other two did (A1-2, A1-3). None of
these monkeys had STN alteration.
B series (n¼10)
This series had kainic acid injections into the STN area and
were divided into two main groups:
B1 (n¼5): STN lesions followed by MPTP treatment
(11.6 3.3 days later).
B2 (n¼5): MPTP treatment followed by STN lesions (6 0.7
days later).
C series (n¼10)
This series had continuous DBS into the STN area and were
divided into two main groups:
C1 (n¼5): DBS of STN followed by MPTP treatment (7 0.5
days later). Two of these monkeys (C1-1, C1-4) died during
recovery after surgery and it was not possible to recover any data
from them.
C2 (n¼5): MPTP treatment followed by DBS of STN (6 0.5
days later).
The rationale behind the time periods for STN alteration after
MPTP treatment (B2–C2 series) was to ensure adequate time for
the dopaminergic cells to be exposed to the toxicity of MPTP and
hence for the degenerative process to begin. In similar fashion, the
rationale behind the time periods of MPTP treatment after STN
alteration (B1–C1 series) was to ensure adequate time for the STN
axons to degenerate or become under the influence of DBS; hence
we could be confident of maximum effect of our lesions or DBS
(Ashkan et al., 2004, 2006).
D series (n¼5)
This series of monkeys did not have MPTP treatment.
All underwent continuous DBS of the STN for nearly 7 months
(201 4.5 days).
For the B, C and D series, STN alterations (lesion or DBS) were
always on the right-hand side (RHS) of the brain; the left-hand
side (LHS) was left untouched and served as a control (see later).
Surgical technique
Anaesthesia was a combination of ketamine (20mg/kg loading
dose, 5mg/kg maintenance im) and diazepam (0.2mg/kg iv). In
addition, 1% lidocaine with adrenaline was used for local
anaesthesia of the scalp. Saline was infused intravenously during
the operation for drug access and hydration. Anteroposterior and
lateral ventriculography X-rays were performed through a
stereotactically placed right lateral ventricular puncture through
which 2ml of ventricular contrast (Iopamiron 200, iodine
200mg/ml, Italy) was injected after 0.5ml of confirmatory air
(Fig. 1A and B). Similar to the protocol used in surgery for PD
patients, the coordinates for stereotactic targeting were based on
III ventricular landmarks [Anterior (AC) and posterior (PC)
commissures] obtained from the ventriculograms.
Electrophysiological localization
Electrophysiology was performed—to refine the radiographic
target—simultaneously through four microelectrodes held by a
custom designed electrode holder (Fig. 1C and D). The
microelectrodes (FHC, USA, Tungsten Microelectrode w/Cannula
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 2–4Meg) were preloaded in guide tubes which were then placed
into the four channels of the holder (Fig. 1D). The trajectory was
parallel to the sagittal plane and 20  anterior to the coronal plane.
Electrophysiology was performed from the AC–PC plane, through
the STN, to the substantia nigra pars reticulata (SNr) in 200mm
steps using the Leadpoint
TM system (Medtronic, USA). During a
typical track, the first structure encountered was the thalamus,
recognized by a bursting pattern of discharge. There was then an
area of decreased activity as the electrode tip passed through the
region of the zona incerta. STN was usually encountered 3mm
below the AC–PC line and was characterized by a sudden increase
in the background noise reflecting high cellular density and cells
with bursting activity at frequencies of 40–50Hz (Fig. 1E). The
electrode location within the motor area of STN was verified by
the response of cells (increased firing audible through signal
transduction and amplification) to passive movement of the
contralateral limbs. The entrance of the electrode into the more
ventrally located SNr was identifiable by high, but regular
discharge rate of about 70Hz. Control X-rays were utilized
throughout the procedure to confirm electrode and catheter
location.
STN alterations
Kainic acid lesion
Kainic acid (Sigma, USA) was dissolved in 0.9% NaCl at a
concentration of 1mg/1ml. After the optimal injection site was
determined (by electrophysiology; see above), the microelectrode
was removed and replaced with a cannula of identical length to
the microelectrode. The cannula was then attached to a 25ml
Fig. 1 Lateral (A) and antero-posterior (B) ventriculography X-rays, performed through a stereotactically placed lateral ventricular
puncture (arrows) through which ventricular contrast was injected: *indicates location of III ventricle. (C) Shows the electrode holder
and (D) shows the holder with the microelectrodes in place. Electrophysiology was performed simultaneously through four
microelectrodes and from the AC^PC plane, through the STN, to the SNr. (E) Indicates the characteristic firing pattern seen in the
STN by the microelectrodes; high background noise and cells that show bursting activity. (F) The quadripolar Medtronic electrode
used for DBS. Arrow indicates one of the four contacts; the most appropriate contact (one located within the STN, determined
electrophysiologically) was activated. (G) Shows a lateral X-ray of monkey with DBS electrode within STN (arrow).This electrode was
connected to an implantable pulse generator (arrowhead). (H) Shows an MRI scan, along transverse plane. In each case, the electrode
tract location within STN checked with MRI (arrow).
Survival of dopaminergic cells Brain ( 2 0 0 7 ) P a g e3o f1 7
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 Hamilton syringe driven by a micropump (KD Scientific, USA).
Approximately 5ml of kainic acid solution was infused at a rate of
0.5ml/min. After the injection was completed, the cannula was left
in place for 10min prior to withdrawal.
DBS
After electrophysiological determination of the STN, a chronic
quadripolar DBS electrode (Fig. 1F; Medtronic 3389-28) was
inserted and secured to the skull. The distal part of the electrode
was connected through an extension (Medtronic 7482) to an
implantable pulse generator (Soletra 7426) inserted in a sub-
cutaneous pouch between the shoulders (arrowhead Fig. 1G). The
implantable pulse generator was programmed transcutaneously in
a non-invasive manner using programming consoles (Medtronic
N’Vision). The animals were stimulated in a monopolar fashion
with the electrode contact designated as the cathode ( ), and the
case of the pulse generator designated as the anode (þ). The
stimulating (active) contact (e.g. arrow Fig. 1F) was chosen in
the awake monkey, 24–72h after implantation, based on clinical
observation of benefits, such as improvement of rigidity or
development of dyskinesia and side effects, particularly muscular
contractions. Frequency was set at 130Hz, pulse width at 60ms
and the amplitude between 2 and 3V, immediately below
the threshold of side effects. After surgery, the location of the
DBS electrode within the STN region was checked using MRI
(arrow Fig. 1H).
MPTP treatment
A subacute MPTP model was used as it produces an effective
primate model of PD and it is the most appropriate for
dopaminergic cell survival studies (Ashkan et al., 2006). MPTP
(Sigma, USA; 0.2mg/kg) was administered intramuscularly for
eight days consecutively. Twenty days after the last MPTP
injection, animals were aldehyde perfused (see later). The non-
MPTP-treated monkey of the A series (A1) was perfused after 21
days of clinical evaluation while the monkeys of the D series (D1-
5) were perfused  7 months (201 4.5d) of continuous DBS of
the STN,  8 months (241 17.4d) after implantation of the
electrode.
Clinical evaluation
Animals were assessed in their home cages starting 4 weeks after
their initial arrival. Assessments were performed on five occasions
before the start of MPTP treatment to establish the baseline and
thereafter occurred on a daily basis until sacrifice. On each
occasion, animals were scored independently by two observers
over a 30min period and video taping was used to facilitate this.
A modified Benazzouz scale (Benazzouz et al., 1995; Ashkan et al.,
2006) was applied and the following parameters were rated:
Tremor (0–3), bradykinesia (0–3), change in posture (0–3),
vocalization (0–1), frequency of arm movements (0–3 for each
arm) and the general level of activity (0–3). Minimum score was
zero and maximum score was 19.
Immunohistochemistry and histology
Animals were anaesthetized after intraperitoneal injection of
sodium pentobarbital (50–60mg/kg) and perfused transcardially
with 0.9% saline followed by 4% buffered formaldehyde. Brains
were removed, blocked, immersed in the same fixative for 24h
and then placed in saline with the addition of 30% sucrose until
the block sank. They were then sectioned coronally on a cryostat
at a thickness of 50mm. Every section was collected in sequence;
one series was collected onto gelatinized slides and processed for
routine cresyl violet staining while five series were collected in
phosphate-buffered saline (PBS; free floating) for immunohisto-
chemistry. Sections were immersed in a solution of 10% normal
goat serum and 1% bovine serum albumin (made up with PBS)
for 1h. In some cases, sections were placed in 10% H2O2 in 70%
ethanol for 10min in order to block endogenous peroxidase
activity. Sections were incubated in anti-TH for 48h at 4 C
(1:500; Chemicon, France). The sections were then incubated
with biotinylated anti-mouse (1:200; IgG, Sigma, USA) for 2h at
room temperature. Finally sections were incubated in the avidin–
biotin–peroxidase complex (1:50; Vectastain, France) for 1h at
room temperature. The bound peroxidase molecule was visualized
using 3,3-diaminobenzidine (Sigma, USA). In between each
incubation, the sections were washed several times with PBS.
Sections were mounted on gelatinized slides, dried overnight,
dehydrated in ascending alcohols, cleared in Histoclear and
coverslipped with DPX. For control experiments, the primary
and/or secondary antibodies were replaced by PBS and then
reacted as above. Control sections were immunonegative.
Stereological analysis
The total number of cells was estimated using stereological
methods. Cell counts were made from the ventral sector of the
SNc (Fig. 2). This region was the most clearly defined of the
greater nigral complex and hence formed the focus of our analysis.
Furthermore, this region has been shown to suffer the most death
after parkinsonian insult (Rinne, 1993). TH immunoreactivity and
Nissl staining was used to assess cell number, as to explore
whether cell loss after MPTP insult was due to loss of antigen
expression (TH) or to a loss of the cells themselves (Nissl). In
other words, we explored whether there was functional and/or
true cell saving. TH immunohistochemistry labels ‘healthy’ cells
that express the dopamine phenotype, that is, this labelling
provides an index of function of dopaminergic cells (Javoy-Agid
et al., 1990; Paul et al., 2004). On the other hand, Nissl staining
labels all cells regardless of phenotypic expression. Following
procedures as outlined by previous studies, the outline of the SNc
(from TH-immunostained sections that defines the nucleus most
distinctly; Fig. 2A and B) was drawn and the volume of the region
was calculated using Cavalieri’s formula (e.g. Coggeshall, 1992;
Earle and Mitrofanis, 1996; Oorschot, 1996; Wadwa, 2003; Wright
et al., 2004). The estimated total number of cells within the SNc
was obtained using the optical fractionator method (West, 1999;
Bonthius et al., 2004; Schmitz and Hof, 2005). Systematic random
sampling of locations (with an unbiased counting frame) within
the defined SNc boundaries of every fifth section was undertaken
(by two observers). All cells (nucleolated only) that came into
focus within an unbiased virtual counting space were counted. As
a general rule, the number of cells and volumes (mean of two
observer counts) were expressed as the mean standard error. The
number of SNc cells on the lesion (RHS) side was expressed as a
ratio of cell survival compared to the contralateral (LHS) side. The
number of cells in the STN, from Nissl-stained sections, was
estimated using the same procedures as described earlier. A
percentage of remaining STN cells in the RHS was generated by
P a g e4o f1 7 Brain (2007) B. A.Wallace et al.
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 direct comparison to the number of cells on the LHS in the same
cases. For comparisons between groups, and because of the small
size of the series, a one-way ANOVA test (F-test) was performed.
Comparison of the number of SNc cells (TH
þ and Nissl-stained)
from the two sides of a single animal (or same group) was
undertaken using a paired sample Student t-test (for inequality).
Finally, Pearson’s correlation coefficient (r) was used to assess the
degree of correlation between STN alterations (by volume) on SNc
cell counts.
Results
The results below will be presented in two major parts;
(i) clinical evaluations (ii) anatomical analysis.
VTA
SNc
MG
dorsal
thalamus
SNc
SNr
VTA
A B
C D
77
TH+
TH+ Nissl
Fig. 2 (A) Schematic diagram of coronal sections of monkey brain.The underlined number corresponds to the plate in the brain atlas of
Paxinos et al. (1998).The box indicates the general region where (B)w a st a k e nf r o m .( B )P h o t o m i c r o g r a p ho fT H
þ cells in midbrain (from
box indicated in (A)).The SNc is outlinedçthis is the region (of compacted darkly stained cells) that was measured for area and hence for
further stereological analysis. Photomicrographs of Nissl-stained (C)a n dT H
þ (D) cells in the SNc.These cells, because of their dark
staining and compacted arrangement, were defined easily from surrounding structures. (C) And (D) are photomicrographs of the medial
region of the SNc of the LHS of intact case (A1-1).There were no differences in the morphology of Nissl-stained orTH
þ cells in any of
the cases examined (MPTP/lesioned/DBS). All figures are of coronal sections, dorsal to top, lateral to left. Scale bar¼100 mm.
Survival of dopaminergic cells Brain ( 2 0 0 7 ) P a g e5o f1 7
b
y
 
g
u
e
s
t
 
o
n
 
N
o
v
e
m
b
e
r
 
7
,
 
2
0
1
4
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 Clinical evaluations
Using a modified Benazzouz scale, each monkey was
evaluated clinically (see ‘Materials and methods’ section).
The higher the scores, the greater the degree of clinical
impairment (Benazzouz et al., 1995). A score of 58
indicated the presence of severe parkinsonian symptoms,
including akinesia, bradykinesia, rigidity, postural instabil-
ity, mask-like faces and reduced vocalization. Tremor was
less common and when it occurred, it was of the intention
rather than of the rest type. These clinical evaluations were
mainly global (bilateral) measures. The only one that was
lateralized (unilateral) was arm movements. There were
only minimal differences in the movements of the two
arms, with or without STN alteration; further there were no
observable involuntary movements after STN lesion in any
of our cases. Clinical scores during the period of time prior
to any STN alteration or MPTP treatment remained at zero
for all cases. The scores of the non-MPTP-treated monkeys,
A1-1 and D series, remained at zero.
Figure 3 shows the clinical scores for each of our series
(except non-MPTP-treated cases). Only the peak scores are
shown; as a general rule, they occurred about 10 days after
the last MPTP injection in each case. After reaching their
peak score, all cases showed improved scores, stabilizing at
about 15 days after the last injection. From our evaluations,
it was clear that there were no major differences in the
timetable of recovery between the groups, whether STN
altered or not. Hence, we did not find any major changes in
behaviour and in clinical scores with STN alteration nor
did we detect any behavioural signs of neuroprotection.
This was due, in part, to unilateral alterations (bilateral
ones might have shown changes more clearly) and a limited
survival period (a longer period of more sustained
evaluation may have revealed clearer clinical changes).
Most of the cases in the different groups developed
severe parkinsonian symptoms, although with some
exceptions (Fig. 3). In the C series, two monkeys (C1-5,
C2-5) showed no change from their baseline scores of zero,
while in the B series, one monkey (B1-3) showed only mild
symptoms. These cases nonetheless showed the expected
decrease in SNc cell number with MPTP treatment
(see later section); they are testimony to the variability in
clinical symptoms—and their lack of clear correspondence
to SNc cell loss—in different individuals after MPTP
treatment.
Anatomical analysis
This section, that forms the main focus of our work, will
consider results in each of the experimental series
separately. First, a consideration of dopaminergic cell
morphology and SNc volume in all our series will be given.
Morphology of dopaminergic cells
Figure 2A and B indicate the SNc region from where the
quantitative analysis was undertaken. Figure 2C shows
Nissl-stained cells, while Fig. 2D shows TH
þ cells of the
normal control (A1-1). They serve as typical examples
of the labelling seen in all the experimental series.
In general, there were no differences in the morphology
of Nissl-stained or TH
þ cells of the SNc after MPTP
treatment and/or after STN alteration (not shown).
SNc volume
The SNc volume in the normal control (A1-1) was 17mm
3
on the LHS and 18mm
3 on the RHS. In the MPTP-treated
intact animals (A1-2, A1-3), volumes were slightly smaller,
averaging 14.1 1.1mm
3 on the LHS and 14.8 1mm
3 on
0
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C
l
i
n
i
c
a
l
 
S
c
o
r
e
s
Fig. 3 Clinical scores of MPTP-treated monkeys.Only peak scores are indicated; these occurred about10 days after the last MPTP
injection.Thereafter, all cases had improved scores, stabilizing at about 15 days after the last injection.There were no major differences
in this timetable of recovery between groups.The intact monkey (A1-1) and the D series were not included in this graph since they
were not MPTP-treated and their clinical scores remained zero throughout. Animals with clinical scores 58 were considered parkinsonian.
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 the RHS. In the B series, the SNc volume was very similar
to the MPTP-treated intact animals (A1-2, A1-3), averaging
14.5 0.7mm
3 on the LHS and 13.6 1mm
3 on the RHS
(lesion). These values were not significantly different
(P¼0.44). In the C series, the SNc volume averaged
13.2 0.3mm
3 on the LHS and 12.8 1mm
3 on the RHS
(DBS). These values were not significantly different
(P¼0.28). Finally, for the D series, the SNc volume
averaged 14.4 0.4mm
3 on the LHS and 14.1 0.1mm
3 on
the RHS (DBS). Again, these values were not significantly
different (P¼0.40).
Thus, although STN alteration (either lesion or DBS)
generated a small decrease in the volume of the SNc, this
decrease did not reach significance. When comparing the
volumes of the SNc between series, no significant
differences were found between the B and C series
(P¼0.14; F¼0.19) and the C and D series (P¼0.90;
F¼1.14).
Intact animals: no STN alteration (A series)
Figure 4 shows that the estimated total number of
Nissl-stained (Fig. 4A) and TH
þ (Fig. 4B) cells of A1-1
(non-MPTP-treated intact animal) was  50% higher than
in A1-2 and A1-3 (MPTP-treated intact animals). Our
estimates of the total SNc number in the SNc are in the
range to those reported previously for normal ( 200000,
Hardman et al., 2002;  65000, Poirier et al., 1983) and for
MPTP-treated ( 140000; Luquin et al., 2006) monkeys
(Fig. 4). It should be noted that the fewer overall number
of TH
þ compared to the Nissl-stained cells was probably
due to (i) antibody penetration (Mitrofanis, 1992) and (ii)
not all SNc cells express TH (see McRitchie and Halliday,
1995; Hardman et al., 2002). This phenomenon was evident
in all our series (Figs. 4, 6, 8 and 9).
In these intact animals, there was minimal difference in
the number of Nissl-stained and TH
þ cells of the LHS and
RHS. All three monkeys had a RHS:LHS ratio about 1; if
the value was less than 1, for example, then that would
represent a higher number of cells on the LHS. Overall,
there was slightly more cells on the LHS than on the RHS
in these cases (Fig. 4). The RHS:LHS ratio of cell counts
for A1-1 was 0.98 for Nissl-stained and 0.93 for TH
þ cells.
For A1-2 and A1-3, the RHS:LHS ratio of cell counts
combined was 0.97 0.07 for Nissl-stained and 0.91 0.01
for TH
þ cells.
In summary, these results indicated that our MPTP
regime was effective, mimicking the pathology of PD, that
is, there was a substantial decline in the SNc cell population
after MPTP treatment. Also, the results showed that there
was no significant skew of SNc cell number to one side or
the other in the intact animals.
Kainic acid lesions in STN region (B series)
On the basis of STN and nigrostriatal fibre involvement,
three groups of monkeys were evident from the B1
(STN lesion followed by MPTP) and B2 (MPTP followed
by STN lesion) series. These will be considered later.
bSTN-lesioned
The cases within this group (n¼7; B1-2, B1-3, B2-5, B1-5,
B2-1, B1-1, B2-2) had lesions that included the majority of
the STN. Figure 5A shows the percentage of STN that was
lesioned in each case; in the bSTN-lesioned group, the average
loss of the STN was  80%. Figure 5B shows the topography
of kainic acid lesion in one of our cases (B1-1); Fig. 5C and D
show the lesion site (and non-lesioned side) of the same
animal. In this case, as in all others, the lesion site not only
included the STN, but surrounding structures as well. These
structures included the zona incerta, SNc, SNr and thalamus.
A small portion of the rostral SNc was lesioned in three of
the seven monkeys (B1-2, B2-1, B2-2). In these cases, the
lesions did not have a major effect on our overall counts of
cells in the SNc (see later). Figure 6 shows the estimated
number of Nissl-stained (Fig. 6A) and TH
þ (Fig. 6B) cells in
this group. In each case, there were always more cells, both
Nissl-stained (Fig. 6A) and TH
þ (Fig. 6B), on the RHS
(lesioned) than on the LHS (non-lesioned). This clear skew of
cell number towards the RHS was in contrast to the trend
apparent in the control A series. All seven monkeys in the
bSTN-lesioned group had a RHS:LHS ratio41 (compare to
A series where ratios were51). The average RHS:LHS ratio
RHS
LHS
Nissl-stained cells
Intact animals (A series)
TH+cells
T
o
t
a
l
 
n
u
m
b
e
r
 
(
×
1
0
3
)
0
50
100
150 NoMPTP
NoMPTP
MPTP
MPTP
A1-1 A1-2 A1-3
A1-1 A1-2 A1-3
A
0
50
100
150
B
Cases
Fig. 4 Number of Nissl-stained (A)a n dT H
þ (B)c e l l si nt h eS N c
(ventral sector) in the A series of experiments.The columns
within the grey background shading involve cases that were
MPTP-treated (A1-2, A1-3) while the columns with no grey shading
involve a case that had no MPTP treatment (A1-1). All were intact
animals, with no STN alteration.
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Fig. 5 (A) Graph indicating the percentage of remaining cells in the STN of the RHS after kainic acid injections in the B series of
experiments.The percentage of Nissl-stained cells in STN in RHS was generated compared to the LHS (total number determined using
stereological methodsçsee text for details).The inset indicates the different experimental groups, determined after examination of lesion
sites and degree of STN lesion. (B) Topography of kainic acid lesion in one case of the B series of experiments (B1-1).This case serves as an
example of a successful lesion of much of the STN. Schematic diagrams were constructed with reference to monkey atlas of Paxinos et al.
(1998).The numbers in italics refer to the plates of that atlas. (C)A n d( D) photomicrographs of Nissl-stained sections of the STN in B
series in one case (B1-1). (D) Is of the kainic acid lesion site within the STN (indicated by
 ), while (C) is the non-lesioned side in same
case.Figures are of coronal sections, dorsal to top, lateral to left (C) or right (D). Scale bar¼100 mm.
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 was 1.20 0.08 for Nissl-stained and 1.24 0.12 for TH
þ
cells. The differences between the RHS and LHS in both Nissl-
stained (P¼0.02) and TH
þ (P¼0.0002) cell number were
significant.
bSham
Two of the ten monkeys (B2-3, B2-4) had very small, if any
lesioning of the STN (average loss of  7%; Fig. 5A). In one
monkey (B2-3), no kainic acid was administered from the
catheter, probably because of a mechanical failure of the
delivery system. In this case, there was a clear gliosis
surrounding the catheter track on the outskirts of the
STN and within the zona incerta, but there was no kainic
acid lesion evident. Although a kainic acid lesion was
present in the second monkey (B2-4), it included little of
the STN, sparing nearly the entire nucleus (Fig. 5A). This
lesion was centred mainly on the overlying zona incerta.
For both cases in this group, the number of both Nissl-
stained (Fig. 6A) and TH
þ (Fig. 6B) cells on the RHS and
LHS were similar. In fact, there was a slight skew towards
the LHS. The average RHS:LHS ratio in this group was
0.92 0.01 for Nissl-stained and 0.96 0.01 for TH
þ cells.
bFibres
In one of the ten monkeys of this series (B1-4; Fig. 5A),
there was a lesion of the passing dopaminergic nigrostriatal
fibres; these fibres pass dorsal to the STN, within the region
of the lesion site (Paxinos et al., 1998). This monkey had an
almost complete lesion of the STN, but no lesion to the
overlying zona incerta or underlying SNc. In the SNc, there
were fewer Nissl-stained (Fig. 6A), and in particular, TH
þ
(Fig. 6B) cells of the RHS (lesioned) compared to the LHS
(non-lesioned). The RHS:LHS ratio for this animal was
0.80 for Nissl-stained and 0.60 for TH
þ cells. As noted
earlier, this loss of SNc cells was not due to the lesion-site
encroaching the SNc itself; rather, it was more likely that
the lesion site ablated the nigrostriatal fibres, that then
generated the loss of SNc cells.
Following this latter point, it should be noted that in
some animals of the bSTN-lesioned group, the lesion site
on the RHS did encroach on regions of the rostral SNc
(B1-2, B2-1, B2-2). Despite this, their Nissl-stained and
TH
þ cell numbers were still higher on the RHS than on the
LHS (Fig. 6). Thus, in these cases, we may have in fact
underestimated the RHS:LHS ratios; there should have
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Fig. 6 Number of Nissl-stained (A)a n dT H
þ (B) cells in the SNc (ventral sector) in the B series of experiments.The columns within
the grey background shading involve cases that had a kainic acid lesion to the STN (bSTN-lesioned); those with a striped background
were sham-injected (bSham), while those with no background involved a kainic acid lesion of the STN that included passing nigrostriatal
fibres (bFibres). All cases were MPTP-treated.
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Fig. 7 (A) Graph of the percentage ofremaining cells in STN in the RHS after implantation of the DBS electrodes in the C and D series of
experiments.The percentage of Nissl-stained cells in STN in RHS was generated compared to the LHS (total number determined using
stereological methodsçsee text for details). (B) And (E) Topography of electrode implants in C (B)a n dD( E)s e r i e so fe x p e r i m e n t s .
Schematic diagrams were constructed with reference to monkey atlas of Paxinos et al. (1998).The numbers in italics refer to the plates of
that atlas.Note thatin these cases, the active electrode contact was within the STNitself. (C) And (D) photomicrographs of Nissl-stained
sections of the STN in once case of the C (C) and D (D) series of experiments.The figures show the electrode implant sites within the
STN (indicated by
 ). All figures are of coronal sections, dorsal to top, lateral to right. Scale bar¼100 mm.
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 been even more cells on the RHS, except for their ablation
by kainic acid.
DBS in STN region (C series)
On the basis of electrode location, two groups of monkeys
were evident from the C1 (DBS of STN followed by MPTP)
and C2 (MPTP followed by DBS of STN) series.
cSTN-DBS
The cases in this group had electrode implants within the
STN (n¼5; C1-2, C1-3, C1-5, C2-4, C2-5). Figure 7A
indicates that the physical location of the electrode within
the STN did not cause a major loss of cells within the
nucleus of this group. In each case, the side that had the
STN electrode implant (RHS) had only  5% difference in
total cell number to the side that did not have an implant
(LHS). Figure 7B shows the electrode location in one of our
cases (C2-4); Fig. 7C shows a Nissl-stained section of the
STN with the electrode site in the same case. It should be
noted that, in the cSTN-DBS group, although the electrode
tract was within the STN, there was also parts of electrode
outside of the STN. As mentioned earlier, only one of the
contacts was activated—the one within the STN—while the
others were not (those outside of the STN). In each case,
there were always more cells, both Nissl-stained (Fig. 8A)
and TH
þ (Fig. 8B), on the RHS (DBS) than on the
LHS (no DBS). This clear skew of cell number towards the
RHS was in contrast to the trend apparent in the A series,
but similar to the B series. The average RHS:LHS ratio was
1.19 0.10 for Nissl-stained and 1.20 0.12 for TH
þ cells.
The differences between the RHS and LHS in both
Nissl-stained (P¼0.006) and TH
þ (P¼0.009) cell
number were significant.
cSham
The cases in this group (n¼3) had electrode implants
outside the STN, either just medial to it within the lateral
hypothalamus (C2-1, C2-2) or the zona incerta (C2-3). In
these cases, the number of both Nissl-stained (Fig. 8A) and
TH
þ (Fig. 8B) cells on the RHS and LHS were similar.
In fact, there was a small skew towards the LHS. The
average RHS:LHS cell count ratio was 0.97 0.05 for
Nissl-stained and 0.97 0.08 for TH
þ cells. The differences
between the RHS and LHS in Nissl-stained (P¼0.33) and
TH
þ (P¼0.67) cell number were not significant.
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Fig. 8 Number of Nissl-stained cells (A)a n dT H
þ cells (B) in the SNc (ventral sector) in the C series of experiments.The columns within
the greybackground shadinginvolve cases that had an electrode implant within the STN (cSTN-DBS); thosewith a stripedbackgroundhad
electrode implants outside of the STN (cSham). All cases were MPTP-treated.
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 Chronic DBS of STN (non-MPTP-treated;
Ds e r i e s )
On the basis of electrode location, three groups of
monkeys were evident from the D series. These are
described later.
dSTN-DBS
Two monkeys had electrode implants within the STN
(D4, D5). Figure 7A indicates that, as with the C series, the
physical location of the electrode within the STN did not
cause a major loss of cells within the nucleus. Figure 7E
shows the topography of the electrode in one of the D
series (D5); Fig. 7D shows a Nissl-stained section of the
STN with the electrode site in the same case. The number
of Nissl-stained (Fig. 9A) and TH
þ (Fig. 9B) cells on the
RHS (DBS) and LHS (no DBS) were approximately
equal in both monkeys of this group (D4, D5).
The RHS:LHS ratios averaged 1.04 0.1 for Nissl-stained
and 0.96 0.5 for TH
þ cells. There was no clear skew
of SNc cell numbers towards any particular side of
the brain.
dSham
One monkey (D1) had the electrode located outside of
the STN, within the zona incerta. The number of both
Nissl-stained (Fig. 9A) and TH
þ (Fig. 9B) cells on the
RHS and LHS were similar in this one case (D1), with
the RHS:LHS ratio being 0.95 for Nissl-stained and
1.15 for TH
þ cells.
dFibres
The other two monkeys (D2, D3) had their electrodes
within the STN but also included passing nigrostriatal
fibres; the most distal part of their electrodes also
encroached the main body of the SNc. The two monkeys
of this group (D2, D3) had fewer Nissl-stained (Fig. 9A)
and TH
þ (Fig. 9B) cells on the RHS compared to the LHS.
The RHS:LHS ratio averaged 0.17 0.02 for Nissl-stained
and 0.12 0.04 for TH
þ cells. The fewer SNc cells in the
RHS of these cases was presumably as a result of physical
damage of the nigrostriatal fibres (just dorsal to STN) and/
or of the SNc by the electrode itself. Such instances may
occur more readily in the monkey brain, mainly because we
used the same DBS electrodes used for the larger human
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Fig. 9 Number of Nissl-stained cells (A)a n dT H
þ cells (B) in the SNc (ventral sector) in the D series of experiments.The columns within
the grey background shading involve cases that had an electrode implant within the STN (dSTN-DBS); thosewith a stripedbackgroundhad
electrode implants outside of the STN (dSham) and those with no background had the electrodes within the STN but included many
nigrostriatal fibres of passage (dFibres). All cases were not MPTP-treated.
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 brain. Hence, some adverse damage to surrounding
structures was perhaps not surprising.
Comparisons between series and groups
In the section that follows, the number of Nissl-stained and
TH
þ cells in the SNc of the different series and groups will
be compared.
STN alterations
There were no significant differences in the number of both
Nissl-stained (P¼0.54; F¼1.19) and TH
þ (P¼1.14;
F¼1.01) cells on the RHS (altered) of the bSTN-lesioned
and cSTN-DBS groups.
Controls (MPTP-treated intact, b,cSham, LHS of STN
alteration cases)
When comparing all our MPTP-treated ‘control’ cases, we
found no significant differences in the number of cells on
the RHS of the bSham, cSham and A2–A3 groups. This was
the case for both Nissl-stained (P¼0.96; F¼0.032) and
TH
þ (P¼0.49; F¼0.83) cells. In addition, we found no
significant differences between the number of cells on the
RHS of these controls and the LHS of the STN alteration
(bSTN-lesioned and cSTN-DBS) groups. This was the
case for both Nissl-stained (P¼0.08; F¼2.68) and
TH
þ (P¼0.12; F¼2.12) cells. Thus, the LHS of the
STN alteration groups may be considered satisfactory
controls.
STN alterations versus controls
There was a significant difference in the number of Nissl-
stained (P¼0.002; F¼15.56) and TH
þ (P¼0.002;
F¼10.0) cells on the RHS (altered) of bSTN-lesioned and
cSTN-DBS groups, compared to the MPTP-treated controls
(MPTP-treated intact, b,cSham and LHS of STN alteration
cases; see above).
STN lesion versus SNc number
There was a significant correlation between the percentage
of cells lesioned in the STN (Fig. 5A) to the number
of both Nissl-stained (P¼0.0001; r¼0.89) and
TH
þ (P¼0.01; r¼0.81) cells in the SNc in each case
(Fig. 6). Thus, the larger the STN lesion, the higher number
of cells in the SNc were evident.
MPTP insult versus SNc cell saving
We also found that the severity of MPTP insult on Nissl-
stained cell number was related inversely to the magnitude
of asymmetry in the SNc on the RHS and LHS (P¼0.0001;
r¼ 0.81). Hence, the more severe the MPTP insult, than
the smaller the dopaminergic cell saving with STN lesion. A
similar relationship was apparent for the TH
þ cells, but this
did not reach statistical significance (P¼0.29; r¼ 0.43).
B 1a n dC 1v e r s u sB 2a n dC 2s e r i e s
Finally, we compared the differences in estimated number
of Nissl-stained and TH
þ cells on the RHS (altered)
between the B1 and B2 and C1 and C2 series. Only
monkeys within the bSTN-lesioned or cSTN-DBS group
were considered. There were no significant differences in
the estimated number of Nissl-stained (P¼0.16; F¼2.23)
and TH
þ (P¼0.75; F¼5.97) cells between the B1 and B2
series and between the C1 and C2 series. Thus, although
there might have been differences in the time-periods
between lesion and perfusion in the B series (B1¼ 40d;
B2¼ 14d) and between DBS and perfusion in the C series
(C1¼ 35d; C2¼ 15d), these differences did not
manifest in significantly different numbers of cells in
the SNc.
Summary
A clear pattern was evident from our results. After kainic
acid lesion or DBS of the STN, there were always more
Nissl-stained and TH
þ cells in the SNc on the side that had
STN alteration. This finding is illustrated further in Fig. 10.
Results from two cases are shown, one from a kainic acid
lesion of the STN (Fig. 10A–D) and the other from a DBS
of the STN (Fig. 10E–H). These cases serve as examples of
the patterns seen in all other corresponding cases. In both
cases, there were more Nissl-stained cells in the SNc of the
side that had the STN either lesioned with kainic acid
(Fig. 10D) or underwent DBS (Fig. 10H), compared to the
non-lesioned (Fig. 10C) or non-DBS (Fig. 10G) sides.
Discussion
Our most striking finding was that there were significantly
more (20–24%) dopaminergic cells in the SNc of the MPTP-
treated monkeys that had STN alteration, either with kainic
acid lesion or DBS, compared to ‘controls’ (MPTP-treated
intact animals, b,cSham and LHS of STN alteration cases).
This indicated that removal of the glutamatergic STN in
MPTP-treated monkeys saved dopaminergic cells. Our results
also showed that after long-term DBS of the STN, there was
no change in SNc cell number.
Comparison with previous studies
Our study is the first to report on the patterns of
dopaminergic cell survival in SNc after both lesion and
DBS of the STN in MPTP-treated monkeys. There have
been several other studies that have explored cell survival
using different approaches and/or animal models of PD.
Such studies have involved STN lesions (6OHDA-lesioned
rats: Piallat et al., 1996; Chen et al., 2000; Carvalho and
Nikhah, 2001; Paul et al., 2004; 3 nitroproprionic
acid-lesioned rats: Nakao et al., 1999) or DBS (6OHDA-
lesioned rats: Maesawa et al., 2004; Temel et al., 2006), as
well as PpT lesions (MPTP-treated monkeys: Takada et al.,
2000). These studies have reported between 15 and 50%
Survival of dopaminergic cells Brain (2007) Page13 of17
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Fig. 10 Schematic diagrams (A, E) and photomicrographs (C, D,G,H) of Nissl-stained cells in the SNc after kainic acid lesion. (A^D)
or DBS (E^H) of the STN.Two cases are shown; B1-1 (A^D) and C1-2 (E^H).The lesion (B) and electrode (F) sites are shown also.
In the schematic diagrams, one black circle represents one cell (A, E). All figures of coronal sections.The grey box in the schematic
diagrams (A, E) indicate general region where photomicrographs were taken from. Note that there were more cells in the SNc on the
side that had the STN alteration (RHS) than on the non-alteration LHS) side. Scale bar¼100 mm.
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 saving of SNc cells after STN or PpT alteration in
parkinsonian cases. Despite differences in design, the overall
magnitude of dopaminergic cell survival found in our study
is comparable to that found in these previous studies.
It should be noted that Luquin et al. (2006) have
reported recently no dopaminergic cell saving in MPTP-
treated monkeys with prior STN lesion. This result is
against the trend of previous (and our) findings, and
considering that they followed an approach similar to the
previous (and our) studies, it is difficult to interpret.
However, their MPTP dosing was severe and this resulted
in a massive loss of dopaminergic cells ( 85%). This was
perhaps too acute for any saving to occur; our study, for
instance, generated a subacute dopaminergic cell loss
( 50%) and hence was more likely to reveal any saving
(see later). Further to this point, our results indicated that
the greater the MPTP insult, then the less cell saving occurs
in the SNc with STN alteration.
Although most studies on animal models of PD provide
evidence for dopaminergic cell saving (see earlier), the
clinical evidence for such a phenomenon is largely lacking.
On one hand, there are observations of PD patients with
slower rates of disease progression after DBS (Østegaard
and Sunde, 2006; Benabid, personal observations). On other
hand, a recent PET study reports that DBS does not halt
disease progression (Hilker et al., 2005). It is clear that
more clinical studies are needed to clarify the issue of
dopaminergic cell saving, particularly some that address
the issue directly.
Finally, the fact that both TH
þ and Nissl-stained cell
number was higher in the MPTP-treated monkeys that had
STN alteration, indicated that there was both a functional
and a true cell saving. That there was an actual increase in
cell survival in the SNc, not just a rescue of the
dopaminergic phenotype. This result confirms the findings
of Takada et al. (2000), but not of Paul et al. (2004).
One may argue that it is difficult to compare the findings of
these previous studies and ours, mainly because of the
different experimental designs. Each study had a different
means of cell labelling (tracer-labelled versus Nissl-stained),
animal models of the disease (6OHDA-lesioned rats versus
MPTP-treated monkeys), method of elimination (kainic
acid lesion versus DBS) and neural centre eliminated
(STN versus PpT). Perhaps a more insightful comparison
on the issue of functional versus true saving may come
from a study that incorporates a common design.
Evidence for neuroprotection of
dopaminergic cells with STN alteration
We were confident that the skew in SNc cell number
towards the STN alteration sides (RHS) of the bSTN-
lesioned and cSTN-DBS groups was not due to a natural
asymmetry in the MPTP treatment. This was because we
found symmetry in SNc cell number in all the MPTP-
treated controls (MPTP-treated intact animals, b,cSham and
LHS of STN alteration cases), indicating that MPTP
affected the SNc of both sides equally. Thus, our finding
of a consistently higher number of dopaminergic cells of
the RHS in every single case of the bSTN-lesioned and
cSTN-DBS groups supported the presence of dopaminergic
cell saving after STN alteration. Further to this point, we
found that in the bSTN-lesioned group, the magnitude of
the SNc cell saving was correlated to the size of the STN
lesion; the greater the STN lesion the larger the SNc
cell saving.
The mechanism that generated dopaminergic cell neuro-
protection in the bSTN-lesioned and cSTN-DBS groups is
not known. However, one may make the following
speculation. The STN has been reported to have a small
but distinct input to the SNc (Hammond et al., 1983;
Parent and Smith, 1987). In parkinsonian cases, the STN
(and consequently the SNc input) is overactive and hence
may generate glutamate excitotoxicity (e.g. Piallat et al.,
1996; Maesawa et al., 2004; Temel et al., 2006). This
phenomenon could exacerbate the degeneration of dopa-
minergic cells generated initially by the parkinsonian insult.
Thus, our STN alterations may have removed or inhibited a
source of glutamatergic input to the SNc and lead to the
neuroprotection or saving of dopaminergic cells. Indeed,
the STN—largely because of its hyperactivity in PD and its
amenability to surgical manipulation (see ‘Introduction’
section)—has been a primary target for reducing the
glutamatergic input to SNc.
It is important to note that we did not find any
neuroprotection in the SNc of our sham cases, those that
had lesions or electrode locations outside of the STN. In
particular, we would like to consider the sham cases that
included the overlying zona incerta (B2-4; C2-3). The zona
incerta has also been shown to be overactive in parkinso-
nian cases (Pe `rier et al., 2000), has a small glutamatergic
projection to the SNc (Heise and Mitrofanis, 2004), and
when lesioned or under DBS, has been reported to alleviate
parkinsonian symptoms (e.g. Nandi et al., 2002). Our
results show that, unlike the STN, alteration of the zona
incerta did not result in dopaminergic cell saving. Perhaps
the efficacy of the glutamatergic input from the STN is
greater than the one from the ZI, and this may result in
greater glutamate toxicity by the STN in parkinsonian cases.
Impact on SNc from long-term cases and
mechanism of DBS
Although our study did not address the issue of the
mechanism of DBS directly, our outcome(s) prompt the
following comments. There were no differences in SNc cell
number between the bSTN-lesioned and cSTN-DBS groups
indicating that DBS of STN generated the same effect as
STN lesion. Furthermore, in the long-term DBS cases
(dSTN-DBS), there were no differences in SNc number
between the DBS and non-DBS sides. Hence, our results
support the idea that DBS inhibits activity in the STN
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 rather than perhaps activate it (see Benabid et al., 2002;
Ashkan et al., 2004). If DBS activated the STN, then one
would have expected more glutamatergic activity in the SNc
and perhaps more cell death (particularly in dSTN-DBS).
This result is prevalent because there are studies that have
reported that DBS of STN actually increases, not decreases,
the glutamate release in target structures (Windels et al.,
2000; Bruet et al., 2001). These previous reports do not find
strong support in our findings.
Limitations of study
A major limitation of this study was the small number of
animals used. Ideally, we would have examined more cases
for each series and developed another series that involved
longer periods of DBS. Furthermore, it would have been
advantages to explore patterns of neuroprotection in cases
with different MPTP dose regimes. Our regime, although
ideal in the sense that it did not generate an acute death of
dopaminergic cells, thereby allowing time for therapeutic
intervention (Ashkan et al., 2006), was limited in the
following way. It did not mimic PD in humans in the fact
that cell death was limited to 50%, and not as extensive as
would be seen normally in PD when first diagnosed
(70–80%; Ashkan et al., 2004); furthermore, we found that
the greater the MPTP insult then there is a smaller degree
of dopaminergic cell saving. The ethics and restricted
availability of using primates for research were the overall
limiting factors. Nonetheless, we feel that with the animals
available to us, we have generated important information
on issues relating to PD, information that is applicable to
humans.
Another limitation of this study—and this is related to
limited animal numbers also—was that we could not
undertake an extensive clinical evaluation of the MPTP-
treated monkeys that had STN alteration. This was partly
because the MPTP model we used was designed to explore
dopaminergic cell survival as measured from anatomical
analysis (histological staining) and not from clinical
evaluations and also because of our particular behavioural
scoring assessments (Benazzouz et al., 1995). We made
unilateral STN alterations, and in theory, such alterations
would have affected the contralateral limbs. Of our
behavioural assessments (e.g. tremor, bradykinesia, posture,
vocalization, arm movements and general activity level),
only one of the six was a unilateral measure (arm
movements), while all others were global bilateral assess-
ments. Hence, the impact of the unilateral STN alteration
in these assessments would have been minimal (there was,
at best, only mild asymmetry in arm movements; see
‘Results’ section). Furthermore, if our survival period was
longer, we would have undertaken a more sustained
evaluation and this might have revealed clearer clinical
changes.
Finally, although our results are highly suggestive, we do
not show conclusively that a reduction in glutamate
excitotoxicity after STN alteration in parkinsonian cases
was the cause of the dopaminergic cell saving. Future
studies may explore this issue further with, for example,
pharmacological methods.
Conclusions
Our results indicated that after either STN lesion or DBS in
MPTP-treated monkeys, there was a 20–24% saving of
dopaminergic cells. Thus, STN alteration may have offered
neuroprotection to dopaminergic cells, those that would
normally die as part of the disease process. Despite the
limitations of our use of a primate model of PD, our results
are highly applicable to humans; they offer hope that here
we may have a therapeutic tool that not only treats the
symptoms of the disease (e.g. see Benabid et al., 2002;
Ashkan et al., 2004), but slows down the pathology
also. This is a feature currently available drug therapy
does not do.
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